Olaparib for BRCA-related prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial studies how well olaparib works for men with metastatic castration-resistant prostate cancer that has a BRCA mutation. It looks at results from real-world use, not a controlled study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread to other parts of the body (metastatic).
- Your cancer is castration-resistant, meaning it keeps growing even when testosterone is lowered.
- You have a BRCA gene mutation (a change in a gene that helps repair DNA).
- You are being treated with olaparib as part of your regular care, not in a clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding a medicine called olaparib to radiation helps men with high-risk prostate cancer. You may receive radiation alone or radiation plus olaparib, and the study looks at whether the combination works better.
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
This study compares two treatments for prostate cancer that has spread and has specific gene changes (BRCA or related genes). It aims to see which treatment works better for people whose cancer has stopped responding to other hormone therapies.
This study looks at how well the combination of two drugs, olaparib and abiraterone, works for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if this treatment helps patients live longer and feel better in real-world settings.
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.